Diffuse Large B Cell Lymphoma Market Overview

Following the release of our latest ebook, this is the first blog post in this series focusing on Diffuse Large B Cell Lymphoma, the most common form of Non Hodgkin Lymphoma (NHL). The DLBCL market is experiencing considerable growth; it is predicted to reach a size of almost USD 4.3 billion by 2022.

The insights shared here, and in the eBook that you can download for free hereare taken from AplusA’s syndicated DLBCL market tracker. The research features insights from at least 100 US and 250 European hematologist / oncologists. 

New AplusA eBook Covers the DLBCL Market

Introducing the latest eBook in our Hemato-Oncology series

 

Enhancing Traditional Research Methods with Social Media Listening

How do social media intelligence insights enhance your capability to make data-led business...

Primary vs Secondary Data

A thorough and agile tracking study can aid marketers to envision emerging trends, consumer...

COVID-19 INFO #4 Data Collection in 35+ Countries

This series of INFO posts is designed to keep you updated with the key developments in our...

Planning a Tracking Study: Aligning Marketing and Market Research Teams

In an increasingly competitive landscape, pharmaceutical companies are required to assess the...

French GPs React to COVID-19: AplusA Poll Wave 4

The latest results from our ongoing poll among French GPs monitoring their experiences and...

French GPs React to COVID-19: Results from AplusA Poll Wave 3

The latest results from our ongoing poll among French GPs monitoring their experiences and...

French GPs React to COVID-19: Results from AplusA Poll Waves 1 and 2

General practitioners are an essential line of defense within the healthcare system in the fight...

COVID-19 INFO #3: Data Collection and More

As the COVID-19 situation develops and as AplusA teams have been receiving questions regarding...